FormalPara Key Summary Points

Head-to-head (H2H) trial evidence regarding the performance of novel therapies versus their competitors is often lacking.

Indirect treatment comparisons (ITC) allow the results of existing trials to be compared in a rigorous way and can help to bridge knowledge gaps when H2H comparisons are not available.

Baricitinib represents an approved oral treatment option for adult patients with moderate-to-severe AD that offers similar efficacy on the Eczema Area and Severity Index (EASI)75 and Dermatology Life Quality Index (DLQI) to dupilumab when indirectly compared.

Baricitinib potentially offers more rapid improvement in itch, a key symptom for patients, than dupilumab when indirectly compared.

Introduction

Baricitinib, a selective Janus kinase (JAK)1/JAK2 inhibitor, is approved in several countries for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy [1]. It has proven effective both as monotherapy and in combination with topical corticosteroids (TCS) [2, 3].

At present, there are no existing head-to-head (H2H) trials comparing the efficacy of baricitinib with other approved systemic therapies available for the management of AD in this patient population. In such circumstances, methodological tools such as indirect treatment comparisons (ITC) are often employed by researchers [4, 5]. ITC methodologies use the results of direct comparisons with a common comparator, such as placebo (PBO), to evaluate the relative efficacy of different interventions. To support physicians when choosing appropriate treatments for AD, we conducted an ITC across all approved systemic therapies for the treatment of moderate-to-severe AD in adults with PBO-controlled randomized controlled trial evidence.

Methods

To identify relevant studies for our ITC, we systematically reviewed the literature for placebo-controlled trials evaluating systemic therapies in adults with moderate-to-severe AD over four waves starting in 2018 with updates in 2019, and May and December 2020. Eligibility criteria for the review were: studies in adults with confirmed moderate-to-severe AD; randomized controlled trials of a comparative investigation (one of which could be PBO); and studies published in English or German. We interrogated MEDLINE and Embase, both via Ovid Search Platform, and The Cochrane Central Register of Controlled Trials (CENTRAL) for published studies as well as ClinicalTrials.gov (http://clinicaltrials.gov/), the International Clinical Trials Registry Platform Search Portal, and the search portal of the World Health Organization to identify potentially relevant studies based on ongoing trials.

The only approved treatments with PBO-controlled trial data identified by the review at this time were dupilumab [6] and baricitinib. The approved dose of dupilumab (300 mg subcutaneously every 2 weeks following a loading dose of 600 mg) [7, 8] was then indirectly compared with baricitinib 2/4 mg once daily [1] using PBO as the common comparator (Fig. 1). When treatment data were available from more than one study versus PBO, standard meta-analysis methods were applied before conducting ITC by means of the Bucher methodology ITC [5].

Fig. 1
figure 1

Structure of ITC analysis of BARI 2/4 mg versus DUPI 300 mg Q2W. BARI baricitinib, DUPI dupilumab, ITC indirect treatment comparison, QxW every x weeks, TCS topical corticosteroids. Population A: patients who were intolerant of, had contraindications to, or did not respond to topical treatments. Population B: patients who were also intolerant of, had contraindications to, or did not respond to, cyclosporine

Patient-level data were available for all baricitinib studies, whereas for dupilumab outcomes, data were extracted from the published literature. The ITC was conducted in two patient populations with subcohorts: population A and population B. Population A consisted of two cohorts, while population B included only one cohort:

Population A: patients who were intolerant of, had contraindications to, or did not respond to topical treatments

  • Cohort 1: patients receiving baricitinib or dupilumab as monotherapy

  • Cohort 2: patients receiving baricitinib or dupilumab in combination with TCS

Population B: patients who were also intolerant of, had contraindications to, or did not respond to cyclosporine:

  • Cohort 1: patients receiving baricitinib or dupilumab in combination with TCS

The ITC was based on the relative efficacy (relative risk [RR]) of the two agents assessed versus PBO for each of the binary outcomes. Where RRs were > 1, results favored baricitinib, while RRs < 1 favored dupilumab. For Dermatology Life Quality Index (DLQI) assessments, the ITC was based on mean difference in change from baseline (MDcfb). MDcfb > 0 favored dupilumab while MDcfb < 0 favored baricitinib. An overview of the population groups is provided in Table 1.

Table 1 Relevant trials identified by systematic literature review

Informed by the primary and key secondary endpoints common across the trials identified in the systematic literature review, we assessed the following efficacy outcomes in our study at week 4 and again at week 16: the proportion of patients with ≥ 75% improvement in Eczema Area and Severity Index (EASI75), the proportion of patients with ≥ 4-point improvement in itch Numeric Rating Scale (NRS) from baseline (peak daily pruritus NRS score used as equivalent; both instruments measure worst level of itch within the past 24 h [9,10,11]), and change from baseline (CFB) in Dermatology Life Quality Index (DLQI).

Missing data were accounted for by non-responder imputation (NRI) for binary outcomes, while for the DLQI, least-squared means were selected from the relevant included studies. Patients in receipt of rescue treatment or who discontinued treatment were considered non-responders. Statistical analyses were conducted using the CHEETAH tool (Indirect Comparison on results from 2 Meta-Analyses version 1.1), a program developed by Eli Lilly based on the R package “meta” [12].

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Results

At the time of the systematic literature review (SLR), nine parallel PBO trials (four baricitinib and five dupilumab) covering 3364 patients were identified to inform the ITC (Table 1). Baseline characteristics for each of the trials are given in Table 2 and are consistent with comparable disease severity based on EASI, itch, and DLQI scores across all included studies. The results of the ITC analysis are summarized in Table 3. In population A at week 4, there was no significant difference between EASI75 response rates for either treatment group, though RR values numerically favored both baricitinib 2 and 4 mg. Similarly, at week 16 there was no statistically significant difference, though in this instance, RR values numerically favored dupilumab. This pattern was replicated in population B.

Table 2 Baseline characteristics of patients in monotherapy studies included in the ITC
Table 3 Results of the indirect treatment comparison of baricitinib and dupilumab in adult patients with moderate-to-severe atopic dermatitis (AD)

With respect to ≥ 4-point improvement in itch NRS from baseline between baricitinib 2 or 4 mg and dupilumab in either monotherapy or TCS combination therapy studies at week 16, no statistically significant differences were evident, although RR values numerically favored dupilumab except for baricitinib 4 mg in population B. At week 4, however, ≥ 4-point itch NRS improvement was significantly more likely to be seen with baricitinib 4 mg than dupilumab in population A for both monotherapy and TCS combination trials. In population B, there were no statistically significant differences between baricitinib 2 or 4 mg compared with dupilumab in achieving ≥ 4-point itch improvement at week 16; RR values numerically favored dupilumab for these comparisons apart from the ≥ 4-point itch improvement seen in baricitinib 4 mg.

For DLQI, no significant differences were observed in MDcfb between baricitinib 4 mg and dupilumab as monotherapy or TCS combination therapy in either population at week 4 or week 16. However, DLQI at week 4 significantly favored dupilumab over baricitinib 2 mg in the population A monotherapy group. At week 16, DLQI MDcfb significantly favored dupilumab versus baricitinib 2 mg as both monotherapy in population A and TCS combination therapy in population A. This difference was also seen in population B at week 16 in our analysis. While these differences were statistically significant, they did not meet the criteria for being clinically meaningful, where a meaningful clinical difference has been determined to be 4 [13].

Discussion

This indirect comparison analysis found that baricitinib and dupilumab might have similar efficacy across EASI75, ≥ 4-point improvement in itch NRS, and DLQI improvement (baricitinib 4 mg) after 16 weeks of treatment, confirming the findings of a recently published network meta-analysis (NMA) and extending them to an earlier time point (week 4) [14].

For earlier time points, baricitinib 4 mg was associated with a higher likelihood of an improvement in itch relative to dupilumab. This finding is largely in keeping with the existing evidence on baricitinib and other JAK 1/2 inhibitors, where improvements in itch have been observed as early as one day after treatment initiation [15, 16]. When asked, patients often rate itch as the symptom they find most bothersome and rate as their most important treatment goal [17, 18]. The increased expression of pruritogens, including TSLP, IL-4, IL-13, and IL-31, is thought to be most important for itch induction in AD [19, 20]. These pruritogens may signal via JAKs [21] and consequently be directly inhibited by baricitinib. Such inhibition may explain baricitinib’s ability to rapidly reduce itch. By week 16, itch improvement was comparable to that achieved by dupilumab. Our findings will serve to support clinical decision-making with regards to treatment options, not only several months into patients’ therapy but also in the early weeks after treatment initiation.

H2H trial data, considered to be the highest form of evidence, can take time to emerge, perhaps delaying access to potentially beneficial therapies for health systems and patients. In such circumstances, NMAs and ITCs like our study can help to provide valuable evidence before H2H data are available. In this case, we chose an ITC framework as only one other drug was identified by the SLR. Several factors should be considered when interpreting our results. Evidence identified by the systematic review was more limited for the TCS combination groups than for monotherapy. Also, it is possible that differences in trial design, such as TCS use not being standardized across trials and different washout periods, limit cross-trial comparability in the AD research landscape. Heterogeneity across trials designs and statistical analysis that impact study outcomes in AD clinical research has been identified as a challenge for healthcare providers [22], though in this instance, there is evidence that these may favor dupilumab [23]. The lack of longer-term follow-up in our analysis also represents a limitation. This was a function of the period of PBO-controlled observation within the trials themselves; comparisons can only be made where there are PBO data available to populate the models. This could be resolved by the conduct of full H2H trials with a longer follow-up period, but such analysis lies outside the scope of this work. We did not assess differences in safety outcomes between the competing treatments.

Conclusions

Baricitinib represents an approved oral treatment option for adult patients with moderate-to-severe AD that potentially offers more rapid improvement in itch, a key symptom for patients, while it might also provide similar efficacy in terms of EASI75 and DLQI outcomes compared with dupilumab based on indirect evidence [24,25,26,27,28].